At ACM Biolabs we are focused on developing novel vaccines using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using multiple antigens and have a growing pipeline of vaccines.

The company is headquartered in Singapore, and has been operational since 2013